Fortress Biotech, Inc. Cash and Restricted Cash
Fortress Biotech, Inc. (FBIO) had Cash and Restricted Cash of $197.80 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $197.80M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $257.06M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $80.60M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $87.44M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $197.80M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $257.06M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $80.60M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $87.44M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $75.61M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $92.56M 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $58.81M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $60.92M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $78.26M 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $85.84M 10-Q · filed 2025-05-15 | |
| 2023-12-31 | $83.36M 10-K · filed 2026-03-31 | |
| 2023-09-30 | $74.75M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $89.21M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $154.92M 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $180.95M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $210.57M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $250.99M 10-Q · filed 2023-08-14 | |
| 2022-03-31 | $289.73M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $307.96M 10-K · filed 2024-03-28 | |
| 2021-09-30 | $254.37M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $276.64M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $291.54M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $235.00M 10-K · filed 2023-03-31 | |
| 2020-09-30 | $220.03M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $199.85M 10-Q · filed 2021-08-16 | |
| 2020-03-31 | $152.52M 10-Q · filed 2021-05-17 | |
| 2019-12-31 | $153.43M 10-K · filed 2022-03-28 | |
| 2019-09-30 | $151.02M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $165.48M 10-Q · filed 2020-08-10 | |
| 2019-03-31 | $132.52M 10-Q · filed 2020-05-11 | |
| 2018-12-31 | $81.58M 10-K/A · filed 2021-04-09 | |
| 2018-09-30 | $91.91M 10-Q · filed 2019-11-12 | $113.56M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $97.39M 10-Q · filed 2019-08-09 | $116.82M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $120.93M 10-Q · filed 2019-05-10 | |
| 2017-12-31 | $110.96M 10-K · filed 2020-03-16 | $131.30M 10-K · filed 2018-03-16 |
| 2017-09-30 | $128.46M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $161.24M 10-Q · filed 2018-08-09 | |
| 2016-12-31 | $82.11M 10-K · filed 2019-03-18 | $104.15M 10-K · filed 2018-03-16 |
| 2015-12-31 | $112.77M 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |